JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lidow, M. S.
Right arrow Articles by Goldman-Rakic, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lidow, M. S.
Right arrow Articles by Goldman-Rakic, P. S.

Vol. 281, Issue 1, 597-603, 1997

Down-Regulation of the D1 and D5 Dopamine Receptors in the Primate Prefrontal Cortex by Chronic Treatment with Antipsychotic Drugs1

Michael S. Lidow, John D. Elsworth and Patricia S. Goldman-Rakic

Section of Neurobiology (M.S.L., P.S.G.) and Department of Pharmacology (J.D.L.), Yale University School of Medicine, New Haven, Connecticut

D2 dopamine receptor antagonism is postulated to be the key to antipsychotic efficacy in the treatment of schizophrenia. Yet the D1 dopamine family of receptors is far more prevalent in the cortical areas of the brain, such as the prefrontal cortex, which have frequently been implicated in schizophrenia. Moreover, the prefrontal cortical D1 sites have recently been shown to be down-regulated by chronic treatment with several commonly used antipsychotic drugs (). To provide further insight into the pharmacological regulation of the D1 class of dopaminergic receptors, we have now used ribonuclease protection assays to examine the regulation of D1 and D5 dopamine receptor mRNAs in the prefrontal cortex and the neostriatum of nonhuman primates after chronic treatment with eight different drugs representing a wide structural and pharmacological spectrum of antipsychotic medications. The medications were administered for 6 months twice daily at doses that fall within the therapeutic range recommended for human patients. The study also included a substituted benzamide, tiapride, which is a D2 antagonist like the eight aforementioned drugs but reportedly lacks antipsychotic activity. Remarkably, all drugs used in this study, including tiapride, down-regulated the levels of both D1 and D5 mRNAs in the prefrontal cortex by 30% to 60% compared with a vehicle control group, whereas mRNAs in the neostriatum were not affected. This observation indicates that a reduction in the levels of prefrontal cortical dopamine receptors of the D1 class may be an obligatory consequence of D2 receptor antagonism and thus may be a pharmacological property of antipsychotic drugs.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 BrainHome page
A. Bertolino, L. Fazio, G. Caforio, G. Blasi, A. Rampino, R. Romano, A. Di Giorgio, P. Taurisano, A. Papp, J. Pinsonneault, et al.
Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia
Brain, February 1, 2009; 132(2): 417 - 425.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. L. Reilly, M. S. H. Harris, M. S. Keshavan, and J. A. Sweeney
Adverse effects of risperidone on spatial working memory in first-episode schizophrenia.
Arch Gen Psychiatry, November 1, 2006; 63(11): 1189 - 1197.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
J. Hirvonen, T. G.M. van Erp, J. Huttunen, S. Aalto, K. Nagren, M. Huttunen, J. Lonnqvist, J. Kaprio, T. D. Cannon, and J. Hietala
Brain Dopamine D1 Receptors in Twins Discordant for Schizophrenia
Am J Psychiatry, October 1, 2006; 163(10): 1747 - 1753.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
C. D. Paspalas and P. S. Goldman-Rakic
Microdomains for Dopamine Volume Neurotransmission in Primate Prefrontal Cortex
J. Neurosci., June 9, 2004; 24(23): 5292 - 5300.
[Abstract] [Full Text] [PDF]

Home page
 NeuroscientistHome page
A. Abi-Dargham and H. Moore
Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia
Neuroscientist, October 1, 2003; 9(5): 404 - 416.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
P. O. Koh, C. Bergson, A. S. Undie, P. S. Goldman-Rakic, and M. S. Lidow
Up-regulation of the D1 Dopamine Receptor-Interacting Protein, Calcyon, in Patients With Schizophrenia
Arch Gen Psychiatry, March 1, 2003; 60(3): 311 - 319.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
P. O. Koh, C. Bergson, A. S. Undie, P. S. Goldman-Rakic, and M. S. Lidow
Up-regulation of the D1 Dopamine Receptor-Interacting Protein, Calcyon, in Patients With Schizophrenia
Arch Gen Psychiatry, March 1, 2003; 60(3): 311 - 319.
[Abstract] [Full Text]

Home page
 Arch Gen PsychiatryHome page
K. A. Albert, H. C. Hemmings Jr, A. I. B. Adamo, S. G. Potkin, S. Akbarian, C. A. Sandman, C. W. Cotman, W. E. Bunney Jr, and P. Greengard
Evidence for Decreased DARPP-32 in the Prefrontal Cortex of Patients With Schizophrenia
Arch Gen Psychiatry, August 1, 2002; 59(8): 705 - 712.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
A. Abi-Dargham, O. Mawlawi, I. Lombardo, R. Gil, D. Martinez, Y. Huang, D.-R. Hwang, J. Keilp, L. Kochan, R. Van Heertum, et al.
Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia
J. Neurosci., May 1, 2002; 22(9): 3708 - 3719.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
N. P. L. G. Verhoeff and S. Kapur
The Role of Neuroimaging in Development of and Treatment With Antipsychotics
Journal of Pharmacy Practice, August 1, 2001; 14(4): 332 - 340.
[Abstract] [PDF]

Home page
 ScienceHome page
S. A. Castner, G. V. Williams, and P. S. Goldman-Rakic
Reversal of Antipsychotic-Induced Working Memory Deficits by Short-Term Dopamine D1 Receptor Stimulation
Science, March 17, 2000; 287(5460): 2020 - 2022.
[Abstract] [Full Text]

Home page
 J. Neurosci.Home page
K. M. Campbell, L. de Lecea, D. M. Severynse, M. G. Caron, M. J. McGrath, S. B. Sparber, L.-Y. Sun, and F. H. Burton
OCD-Like Behaviors Caused by a Neuropotentiating Transgene Targeted to Cortical and Limbic D1+ Neurons
J. Neurosci., June 15, 1999; 19(12): 5044 - 5053.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
E. C. Muly III, K. Szigeti, and P. S. Goldman-Rakic
D1 Receptor in Interneurons of Macaque Prefrontal Cortex: Distribution and Subcellular Localization
J. Neurosci., December 15, 1998; 18(24): 10553 - 10565.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. A. Kelly, M. Rubinstein, T. J. Phillips, C. N. Lessov, S. Burkhart-Kasch, G. Zhang, J. R. Bunzow, Y. Fang, G. A. Gerhardt, D. K. Grandy, et al.
Locomotor Activity in D2 Dopamine Receptor-Deficient Mice Is Determined by Gene Dosage, Genetic Background, and Developmental Adaptations
J. Neurosci., May 1, 1998; 18(9): 3470 - 3479.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Ahlenius, E. Ericson, V. Hillegaart, L. B. Nilsson, P. Salmi, and A. Wijkström
In Vivo Effects of Remoxipride and Aromatic Ring Metabolites in the Rat
J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1356 - 1366.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.